Year Founded
2011
Ownership
Public
Stage
Commercial
Modalities
Small molecule

Hua Medicine General Information

Lead product HuaTangNing (dorzagliatin) approved in China for type 2 diabetes. Sales growing with 740% increase in volume in 2024 vs 2023. Second generation GKA completed Phase 1 SAD study in US.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Shanghai,
China

Drug Pipeline

dorzagliatin
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Hua Medicine's pipeline data

Book a demo

Key Partnerships

Bayer Healthcare (former commercial partner)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Hua Medicine Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Hua Medicine's complete valuation and funding history, request access »

Hua Medicine Investors

F-Prime Capital
Investor Type: Venture Capital
Holding: Minority
Venrock
Investor Type: Venture Capital
Holding: Minority
ARCH Venture Partners
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »